Skip to main content

Advertisement

Table 2 Ongoing adjuvant trials

From: Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy)

Study No. of patients TNM stage Therapy Primary endpoint
US Intergroup E1609 1600 III (IIIB–c), IV (M1a, M1b) Ipilimumab 3 mg/kg or 10 g/kg vs HD-IFN RFS, OS
COMBI-AD 852 III (BRAF V600E/K) Dabrafenib + trametinib vs. placebo RFS
BRIM-8 725 IIC, III (BRAF V600; Cobas) Vemurafenib vs. placebo DFS
EORTC-1325/KEYNOTE-054 900 IIA (> 1 mm met), IIIb–C Pembrolizumab vs. placebo RFS, RFS in PDL1+
CheckMate-238 800 IIIB–C, IV Nivolumab vs. ipilimumab 10 g/kg RFS
US Intergroup S1404 1240 IIIA (N2), IIIB–C, M Pembrolizumab vs. HD-IFN or ipilimumab 10 mg/kg RFS, OS
C heckMate-915 1125 IIIB–D, IV Ipilimumab + nivolumab vs ipilimumab or nivolumab RFS